The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer
- DOI
- 10.1007/s00262-025-04239-1
- Published
- 2025-11-18
- Container
- Cancer Immunology, Immunotherapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s00262-025-04239-1,
title = {The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer},
author = {Chie Kudo-Saito and Hiroshi Imazeki and Kengo Nagashima and Hirokazu Shoji and Kai Tsugaru and Naoki Takahashi and Takeshi Kawakami and Yusuke Amanuma and Takeru Wakatsuki and Fumio Nagashima and Yukiya Narita and Yoshiyuki Yamamoto and Rika Kizawa and Kei Muro and Narikazu Boku},
year = {2025},
journal = {Cancer Immunology, Immunotherapy},
doi = {10.1007/s00262-025-04239-1},
url = {https://doi.org/10.1007/s00262-025-04239-1}
}RIS
TY - JOUR TI - The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer AU - Chie Kudo-Saito AU - Hiroshi Imazeki AU - Kengo Nagashima AU - Hirokazu Shoji AU - Kai Tsugaru AU - Naoki Takahashi AU - Takeshi Kawakami AU - Yusuke Amanuma AU - Takeru Wakatsuki AU - Fumio Nagashima AU - Yukiya Narita AU - Yoshiyuki Yamamoto AU - Rika Kizawa AU - Kei Muro AU - Narikazu Boku PY - 2025 JO - Cancer Immunology, Immunotherapy DO - 10.1007/s00262-025-04239-1 UR - https://doi.org/10.1007/s00262-025-04239-1 ER -
APA
Kudo-Saito, C., Imazeki, H., Nagashima, K., Shoji, H., Tsugaru, K., Takahashi, N., Kawakami, T., Amanuma, Y., Wakatsuki, T., Nagashima, F., Narita, Y., Yamamoto, Y., Kizawa, R., Muro, K., & Boku, N. (2025). The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04239-1
Source records
- crossref · retrieved 2026-09-26T01:04:31.837Z